Wearable Core Body Temperature Monitoring for Early Detection of Cytokine Release Syndrome in Outpatients Receiving CAR T-Cell Therapy
A Randomized Controlled Trial of a Wearable Core Body Temperature Sensor Versus Standard Temperature Monitoring for Early Detection of Cytokine Release Syndrome in Patients Undergoing CAR T-Cell Therapy in an Outpatient Setting
The purpose of this research study is to see if a wearable temperature monitoring patch can detect cytokine release syndrome earlier than traditional oral temperature monitoring.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
This randomized pilot study is designed to evaluate the efficacy of a continuous temperature-monitoring wearable patch in patients receiving CAR-T therapy in the outpatient setting, comparing its performance to standard institutional monitoring protocols.
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Courtney Schepel
- Telefoonnummer: (980) 442-2327
- E-mail: Courtney.Schepel@advocatehealth.org
Studie Contact Back-up
- Naam: Cindy Varga, MD
- Telefoonnummer: 704-355-2000
- E-mail: Cindy.Varga@advocatehealth.org
Studie Locaties
-
-
North Carolina
-
Charlotte, North Carolina, Verenigde Staten, 28204
- Atrium Health Levine Cancer
-
Hoofdonderzoeker:
- Cindy Varga, MD
-
Contact:
- Courtney Schepel
- Telefoonnummer: 980-442-2327
- E-mail: Courtney.Schepel@advocatehealth.org
-
Winston-Salem, North Carolina, Verenigde Staten, 27103
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center
-
Contact:
- John McKay, DO
- E-mail: John.Mckay@wfusm.edu
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Patients:
- Ability to understand and willingness to sign an IRB-approved informed consent
- Age ≥ 18 years at the time of consent
- Scheduled to undergo CAR-T therapy in the outpatient setting at AHWFBCCC
- Ability to read and understand the English and/or Spanish language
- As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study
- Access to a mobile device for the duration of the trial
Provider/Staff:
Provider/staff participants must meet all of the following inclusion criteria to participate in the study:
- Verbally agree to participate
- Hospital at Home outpatient provider/advanced practice provider/nurse of at least one patient participant enrolled on Arm A who completed 14 days of temperature monitoring
Exclusion Criteria:
Patients:
- Planned prophylactic tocilizumab for mitigation of CRS as documented in the clinical trials pathway submission
- History of silicone allergy
- History of Medical Adhesive-Related Skin Injury (MARSI)
- Known skin condition that might preclude safe application of the patch, in the opinion of the enrolling investigator
Provider/Staff:
None
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Ander: Arm A: TempShield Continuous Temperature Monitoring plus SOC Temperature Monitoring
Standard of care oral temperature monitoring plus TempShield continuous temperature monitoring patch |
Patient participants will receive instruction from a research designee regarding use of the TempShield patch and smartphone application for continuous at-home temperature monitoring. Patient participants will complete onboarding of the application on their smartphone with assistance from the research designee, if necessary. Patient participants should place the patch immediately after completion of CAR-T infusion in the outpatient setting, with assistance from the research designee. |
|
Ander: Arm B: SOC Temperature Monitoring
Standard of care oral temperature monitoring |
Standard of care oral temperature monitoring |
|
Geen tussenkomst: Arm C: Provider/Staff
Providers/staff are Hospital at Home personnel who support patients undergoing outpatient CAR-T therapy and who have monitored at least one participant enrolled on Arm A of the study. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Time to first recorded temperature elevation indicative of Cytokine Release Syndrome (CRS)
Tijdsspanne: From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
Time (in hours) from the initiation of CAR-T infusion to the first occurrence of a recorded body temperature elevation of ≥ 100.4°F (38.0°C) during the 14-day post-CAR-T observation period. Participants who do not experience this defined temperature elevation within the 14 days will be censored at the time of their last recorded temperature reading during this window. Reported by arm. |
From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence of temperature elevation indicative of Cytokine Release Syndrome (CRS)
Tijdsspanne: From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
Number of participants who experience at least one recorded body temperature elevation of ≥ 100.4°F (38.0°C) during the 14-day post-CAR-T observation period. Reported by arm. |
From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
|
Incidence of high-grade (grade 2 or higher) Cytokine Release Syndrome (CRS)
Tijdsspanne: From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
Number of participants who experience grade 2 or higher CRS during the 14-day post-CAR-T observation period. Reported by arm. |
From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
|
Time to resolution of Cytokine Release Syndrome (CRS) from temper elevation indicative of CRS (temperature ≥ 100.4 °F)
Tijdsspanne: From the temperature elevation (≥ 100.4 °F) to resolution during the 14 days after CAR-T infusion.
|
Time (in hours) from the from onset of fever indicative of CRS (temperature ≥ 100.4 °F) during the 14-day post-CAR-T observation period to resolution (i.e., when the participant no longer meets the CRS diagnostic criteria). If a participant experiences multiple episodes of CRS during the 14-day post-CAR-T observation period, the duration can be calculated per episode and cumulatively. This will be calculated for participants experiencing CRS (temperature ≥ 100.4 °F) during the 14-day post-CAR-T observation period. Reported by arm. |
From the temperature elevation (≥ 100.4 °F) to resolution during the 14 days after CAR-T infusion.
|
|
Time to intervention after fever detection (temperature ≥ 100.4 °F)
Tijdsspanne: From the temperature elevation (≥ 100.4 °F) to intervention during the 14 days after CAR-T infusion.
|
Time (in hours) from documented temperature elevation of ≥ 100.4° F to clinician intervention (e.g., supportive care, medication followed by observation, etc.). This will be calculated for participants experiencing CRS during the 14-day post-CAR-T observation period. Reported by arm. |
From the temperature elevation (≥ 100.4 °F) to intervention during the 14 days after CAR-T infusion.
|
|
Incidence of admission to the Intensive Care Unit (ICU) due to temperature elevation indicative of CRS
Tijdsspanne: From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
Number of participants admitted to the ICU due to temperature elevation indicative of CRS during the 14-day post-CAR-T observation period. Reported by arm. |
From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
|
Time to discharge after admission to the Intensive Care Unit (ICU)
Tijdsspanne: From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
Time (in hours) from ICU admission to ICU discharge. If a participant has multiple ICU admissions during the 14-day post-CAR-T observation period, the duration will be calculated cumulatively. Reported by arm. |
From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
|
Length of hospital stay
Tijdsspanne: From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
Number of inpatient nights from hospital admission to hospital discharge due to temperature elevation indicative of CRS during the 14-day post-CAR-T observation period. If a participant has multiple hospital admissions due to CRS during the 14-day post-CAR-T observation period, the duration reported will be cumulative across all stays. This endpoint will be calculated for participants admitted to this hospital during the 14-day post-CAR-T observation period due to temperature elevation indicative of CRS. Reported by arm. |
From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
|
Incidence of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Tijdsspanne: From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
Number of participants experiencing ICANS during the 14-day post-CAR-T observation period. Reported by arm. |
From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
|
Largest change in body temperature from baseline recorded during the 14-day post-CAR-T observation period
Tijdsspanne: From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
The maximum numerical difference in body temperature recorded from baseline during the 14-day post-CAR-T observation period. Reported by arm. |
From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
|
The proportion of hours during the 14-day post CAR-T observation period when patch was worn
Tijdsspanne: From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
The proportion of hours during the 14-day post-CAR-T observation period in which at least one valid human body temperature reading (86 °F to 108 °F) was recorded by the wearable patch, defined as Total adherence = (Number of hours with at least one valid temperature reading)/(24*14 hours). This will be calculated for participants randomized to wear the remote temperature monitoring device. |
From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
|
The proportion of paired temperature readings from the temperature patch and an oral thermometer within one degree Fahrenheit in a five-minute window during the 14-day post-CAR-T observation period
Tijdsspanne: From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
The number 5-minute intervals in the 14-day post-CAR-T observation period (from the first patch reading indicating a temperature from 86 °F to 108 °F), when concordance between the temperature patch and an oral thermometer within one degree Fahrenheit was observed. |
From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
|
Patient satisfaction with CAR-T temperature monitoring methods
Tijdsspanne: The Day 14 post-infusion (+28 days) study calendar visit.
|
Patient satisfaction as assessed by the study survey, evaluating satisfaction on a Likert scale where higher scores indicate a higher level of patient satisfaction with the assigned monitoring method (standard of care vs. wearable patch). |
The Day 14 post-infusion (+28 days) study calendar visit.
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Medewerkers
Medewerkers
Onderzoekers
Onderzoekers
- Hoofdonderzoeker: Cindy Varga, MD, Wake Forest University Health Sciences
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Pathologische processen
- Neoplasmata
- Neoplasmata per histologisch type
- Systemisch ontstekingsreactiesyndroom
- Ontsteking
- Schok
- Pathologische aandoeningen, tekenen en symptomen
- Cytokine Release Syndroom
- Neoplasmata, plasmacel
- Health Services Administration
- Kwaliteit, toegang en evaluatie van de gezondheidszorg
- Kwaliteit van de gezondheidszorg
- Kwaliteitsindicatoren, gezondheidszorg
- Zorgstandaard
Andere studie-ID-nummers
Andere studie-ID-nummers
- IRB00158734
- ONC-MM-2501 (Andere identificatie: Atrium Health Wake Forest Baptist Comprehensive Cancer Center)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .